Bio-Gate strengthens presence in the North American market for innovative animal care
- Bio-Gate’s customer launches a new product line for ear infections
- Technological leadership in animal care confirmed
- Additional product launches planned – starting in Q2 2023
Nuremberg/Bremen, 1 February 2023 – Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative technologies and individual solutions for health and hygiene, has developed antimicrobial products for ear care in animals, which are now marketed by our US-based customer and animal health specialist W. F. Young.
The products developed and manufactured by Bio-Gate AG for W. F. Young are sold in North America as part of the “Silver Honey® Rapid Ear Care line” product line. The products are based on the combination of MicroSilver BGTM and Manuka honey. They are used to help treat and help prevent ear infections in small animals. This is done effectively and naturally, and without the use of antibiotics. This makes them currently one of the most innovative products on the market. The excessive use of antibiotics leads to dangerous bacterial resistance in animals, which can potentially be transmitted to other (domestic) animals and even to their owners.
MicroSilver BG™ and Manuka honey have synergistic antimicrobial as well as skin soothing and anti-inflammatory properties, which, when combined in the products of the new ear care line, can help to reduce antibiotic-based therapy. These products in North America are within the recommendations of the German Antibiotic Resistance Strategy (DART) 2020 and 2030, which aims to reduce antibiotic resistance and the use of antibiotics.
Pet owners using these innovative antibacterial ear care products can help reduce the risk of possible antibiotic resistance in their pets.
The Silver Honey® product family already includes a wound care spray and a wound ointment, developed by Bio-Gate, which promote rapid wound healing success with the support of MicroSilver BG™. The US pet care retailer W. F. Young has a broad distribution network and sells its product range in specialty pet retailers, farm supply stores, pet food retailers and also via online retailers. According to the Zentralverband Zoologischer Fachbetriebe Deutschlands e.V., sales for pet supplies in the USA reached around 58.4 billion euros in 2021 and were thus almost twice as large as the Western European market with 29.8 billion euros. In addition, in the USA alone, around 6.5 million dogs suffer from ear infections every year.
Thomas Konradt, Director of Business Development at Bio-Gate AG: “With our innovative developments in animal care products, we are meeting a great global demand. That’s why we want to expand our veterinary business – for both professional and retail customers. Starting in the second quarter of 2023, additional pet care products will be available from us under the brand of the largest pet supply retailers in North America.”
Further information on the effect of MicroSilver BG™ can be found on the website www.microsilver.de and on the homepage of Bio-Gate AG www.bio.gate.de.
Please download the press release here as pdf.
RFH BioTek Inc.
About Bio-Gate AG – The medical technology company Bio-Gate AG develops and markets applications which use unique silver technology to help prevent infections and thus to improve health. Bio-Gate AG’s specialty is using pure silver to treat materials and surfaces that are used in all areas of daily life – thus providing long-term and medically effective protection against bacteria, microorganisms and other pathogens. Bio-Gate AG works in three fields to supply a variety of products that provide antimicrobial protection: material enhancement, surface coating and testing the antimicrobial or anti-adhesive properties of materials. The Nuremberg-based company offers systems that stretch across the entire value-adding chain, from development to approval to production. For more information, please visit www.bio-gate.de.
This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”)). The securities have already been sold.